Epstein-Barr Virus Infections

• 

  Subject Areas on Research

  • A genomic-augmented multivariate prognostic model for the survival of natural-killer/T-cell lymphoma patients from an international cohort. 
  • A malignant lymphoma with histological features and immunophenotypic profile intermediate between EBV-positive diffuse large B-cell lymphoma and EBV-positive classical Hodgkin lymphoma in a 67-year-old female: a "gray zone" lymphoma associated with Epstein-Barr virus in the elderly. 
  • A microRNA signature profile in EBV+ diffuse large B-cell lymphoma of the elderly. 
  • A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas. 
  • Acute Kidney Injury in a Patient With a Kidney Transplant and Posttransplant Lymphoproliferative Disorder: A Quiz. 
  • Acute hepatitis due to epstein-barr virus in an immunocompetent patient. 
  • Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma--is it necessary? 
  • Age-related patterns of cytomegalovirus antibodies accompanying Epstein-Barr virus co-infection. 
  • An Epstein-Barr virus-positive diffuse large B-cell lymphoma presenting as multi-organ failure: a catastrophic lymphomatosis with fulminant visceral organ dissemination resulting in a precipitous death in a 59-year-old female with no identifiable etiology for immunodeficiency. 
  • Association of Epstein-Barr virus with systemic lupus erythematosus: effect modification by race, age, and cytotoxic T lymphocyte-associated antigen 4 genotype. 
  • Biliary stricture secondary to donor B-cell lymphoma after orthotopic liver transplantation. 
  • Cancer Therapy-associated Lymphoproliferative Disorders: An Under-recognized Type of Immunodeficiency-associated Lymphoproliferative Disorder. 
  • Cerebral lymphoma in an adenosine deaminase-deficient patient with severe combined immunodeficiency receiving polyethylene glycol-conjugated adenosine deaminase. 
  • Combined assessment of Epstein-Barr virus viral capsid antigen and Epstein-Barr virus nuclear antigen-1 serology for post-transplant lymphoproliferative disorder risk stratification in adult solid organ transplant recipients. 
  • Concurrent classical Hodgkin lymphoma and plasmablastic lymphoma in a patient with chronic lymphocytic leukemia/small lymphocytic lymphoma treated with fludarabine: a dimorphic presentation of iatrogenic immunodeficiency-associated lymphoproliferative disorder with evidence suggestive of multiclonal transformability of B cells by Epstein-Barr virus. 
  • Decreased survival in hepatitis C patients with monomorphic post-transplant lymphoproliferative disorder after liver transplantation treated with frontline immunochemotherapy. 
  • Distinct interactions of the X-linked lymphoproliferative syndrome gene product SAP with cytoplasmic domains of members of the CD2 receptor family. 
  • EBV-driven B-cell lymphoproliferative disorders: from biology, classification and differential diagnosis to clinical management. 
  • EBV-positive diffuse large B-cell lymphoma in young adults: is this a distinct disease entity? 
  • EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation. 
  • EBV-positive diffuse large B-cell lymphoma of the elderly. 
  • EBV-positive diffuse large B-cell lymphoma of the elderly: 2016 update on diagnosis, risk-stratification, and management. 
  • EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2018 update on diagnosis, risk-stratification and management. 
  • EBV⁺ high-grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: a multi-institutional study. 
  • Endemic Burkitt lymphoma avatar mouse models for exploring inter-patient tumor variation and testing targeted therapies. 
  • Epstein - Barr virus specific cytotoxic T lymphocytes for the treatment of severe epstein-barr virus mucocutaneous ulcer. 
  • Epstein Barr virus nuclear antigen 1 (EBNA-1) peptides recognized by adult multiple sclerosis patient sera induce neurologic symptoms in a murine model. 
  • Epstein-Barr Virus Antibody Titers Are Not Associated with Gastric Cancer Risk in East Asia. 
  • Epstein-Barr Virus DNAemia and post-transplant lymphoproliferative disorder in pediatric solid organ transplant recipients. 
  • Epstein-Barr Virus Genomes Reveal Population Structure and Type 1 Association with Endemic Burkitt Lymphoma. 
  • Epstein-Barr virus DNA load in chronic lymphocytic leukemia is an independent predictor of clinical course and survival. 
  • Epstein-Barr virus in gastric adenocarcinomas: association with ethnicity and CDKN2A promoter methylation. 
  • Epstein-Barr virus induces global changes in cellular mRNA isoform usage that are important for the maintenance of latency. 
  • Epstein-Barr virus perpetuates B cell germinal center dynamics and generation of autoimmune-associated phenotypes in vitro. 
  • Epstein-Barr virus posttransplant lymphoproliferative disorder: update on management and outcomes. 
  • Epstein-Barr virus-associated epithelial and mesenchymal neoplasms. 
  • Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. 
  • Epstein-Barr virus-associated smooth muscle tumor involving the spine of an HIV-infected patient: Case report and review of the literature. 
  • Epstein-Barr virus-associated smooth muscle tumors are distinctive mesenchymal tumors reflecting multiple infection events: a clinicopathologic and molecular analysis of 29 tumors from 19 patients. 
  • Epstein-Barr virus-positive T/NK-cell lymphoproliferative disorders. 
  • Epstein-Barr virus-positive nodular lymphocyte predominant Hodgkin lymphoma. 
  • Epstein-Barr-associated leiomyomatosis and T-cell chimerism after haploidentical bone marrow transplantation for severe combined immunodeficiency disease. 
  • Evaluation of host cellular responses to Epstein-Barr virus (EBV) in adult lung transplant patients with EBV-associated diseases. 
  • Evidence of Epstein-Barr virus heterogeneous gene expression in adult lung transplant recipients with posttransplant lymphoproliferative disorder. 
  • Expanding the Spectrum of EBV-positive Marginal Zone Lymphomas: A Lesion Associated With Diverse Immunodeficiency Settings. 
  • Flow cytometric findings in hemophagocytic lymphohistiocytosis. 
  • Gianotti-Crosti syndrome as the only manifestation of primary Epstein-Barr virus infection: a case report. 
  • High risk of relapsed disease in patients with NK/T-cell chronic active Epstein-Barr virus disease outside of Asia. 
  • Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics. 
  • Hypoxia-inducible factor-1α plays roles in Epstein-Barr virus's natural life cycle and tumorigenesis by inducing lytic infection through direct binding to the immediate-early BZLF1 gene promoter. 
  • Identification of Host Biomarkers of Epstein-Barr Virus Latency IIb and Latency III. 
  • Kidney transplantation using alemtuzumab, belatacept, and sirolimus: Five-year follow-up. 
  • Low incidence of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorders in 272 unrelated-donor umbilical cord blood transplant recipients. 
  • Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. 
  • Lymphocytic vasculitis involving the central nervous system occurs in patients with X-linked lymphoproliferative disease in the absence of Epstein-Barr virus infection. 
  • Monocarboxylate transporter antagonism reveals metabolic vulnerabilities of viral-driven lymphomas. 
  • Oral and extraoral plasmablastic lymphoma: similarities and differences in clinicopathologic characteristics. 
  • Perforin and IL-2 upregulation define qualitative differences among highly functional virus-specific human CD8 T cells. 
  • Post-transplant lymphoproliferative disorder associated with immunosuppressive therapy for renal transplantation in rhesus macaques (Macaca mulatta). 
  • Posttransplant lymphoproliferative disorder after umbilical cord blood transplantation in children. 
  • Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries. 
  • Primary cutaneous giant cell plasmacytoma in an organ transplant recipient: a rare presentation of a posttransplant lymphoproliferative disorder. 
  • Primary cutaneous, composite, Epstein-Barr virus-associated, diffuse large B-cell lymphoma and peripheral T-cell lymphoma. 
  • Relationship Among Viremia/Viral Infection, Alloimmunity, and Nutritional Parameters in the First Year After Pediatric Kidney Transplantation. 
  • Richter transformation driven by Epstein-Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia. 
  • Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis. 
  • Role of Epstein-Barr virus infection in SLE: gene-environment interactions at the molecular level. 
  • SplicerEX: a tool for the automated detection and classification of mRNA changes from conventional and splice-sensitive microarray expression data. 
  • Spontaneous resolution of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. 
  • Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study. 
  • T-cell and T/natural killer-cell lymphomas involving ocular and ocular adnexal tissues: a clinicopathologic, immunohistochemical, and molecular study of seven cases. 
  • TCR repertoire characteristics predict clinical response to adoptive CTL therapy against nasopharyngeal carcinoma. 
  • The Epstein-Barr virus (EBV)-induced tumor suppressor microRNA MiR-34a is growth promoting in EBV-infected B cells. 
  • The Role of EBV in the Pathogenesis of Diffuse Large B Cell Lymphoma. 
  • The Role of EBV-Induced Hypermethylation in Gastric Cancer Tumorigenesis. 
  • The impact of activated p-AKT expression on clinical outcomes in diffuse large B-cell lymphoma: a clinicopathological study of 262 cases. 
  • The role of Epstein-Barr virus in systemic lupus erythematosus. 
  • The role of microRNAs in Epstein-Barr virus latency and lytic reactivation. 
  • The viral and cellular microRNA targetome in lymphoblastoid cell lines. 
  • Time-resolved transcriptomes reveal diverse B cell fate trajectories in the early response to Epstein-Barr virus infection. 
  • To be or not IIb: a multi-step process for Epstein-Barr virus latency establishment and consequences for B cell tumorigenesis. 
  • Uncontrolled Epstein-Barr Virus as an Atypical Presentation of Deficiency in ADA2 (DADA2). 
  • c-Myc Represses Transcription of Epstein-Barr Virus Latent Membrane Protein 1 Early after Primary B Cell Infection. 
• 

  Keywords of People

  • Luftig, Micah Alan, Professor of Molecular Genetics and Microbiology, Cell Biology
  • Stoecker, Maggie Marie, Assistant Professor of Pathology, Pathology